Why the cost conversation misses 50% of the picture
Patients and HR benefits committees that evaluate GLP-1 cost-effectiveness in isolation — $6,000/year drug cost with no offset — get the answer wrong. Obesity is a chronic disease with measurable downstream costs in type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, MASH/NAFLD, osteoarthritis, and cardiovascular events. Meaningful weight loss reduces incidence of all of these. The savings do not appear on the patient’s pharmacy EOB, but they show up in avoided ER visits, avoided cardiology referrals, avoided CPAP durable equipment, fewer medications, and lower absenteeism.
This tool estimates those offsets. The outputs are expected values, not guarantees, and they apply only if you actually have the underlying risk at baseline.
SURMOUNT-OSA: the sleep apnea headline
SURMOUNT-OSA (Malhotra et al., NEJM 2024, N=469) enrolled adults with moderate-to-severe obstructive sleep apnea (AHI ≥ 15) and obesity, randomized to tirzepatide 10/15 mg or placebo for 52 weeks, with and without CPAP use. Results: AHI reduction of 25–30 events/hour on tirzepatide vs ~5–6 on placebo; roughly 42% of tirzepatide patients saw AHI resolution to < 5 events/hour — functionally curing OSA in the trial window. Oxygen desaturation indices improved, blood pressure fell, and patient-reported Epworth Sleepiness Scale scores dropped. For a patient with BMI 34 and moderate OSA on CPAP, successful AHI resolution eliminates $800–$1,200/year in CPAP equipment and studies, reduces long-term CV risk attributable to OSA, and eliminates the substantial quality-of-life cost of CPAP adherence. FDA approved tirzepatide for moderate-to-severe OSA in obese adults in December 2024, making this the first pharmaceutical indication for OSA — and a major driver of the “Zepbound for OSA” PA path that opened for patients with the documented diagnosis.
The big three: T2D prevention, ASCVD reduction, OSA resolution
Type 2 diabetes avoidance. The ADA puts average annual cost of managing T2D complications at roughly $12,000–$14,000/year per patient in direct medical spend (medications, monitoring, complications, ER). The Diabetes Prevention Program and STEP 3 trial data suggest semaglutide 2.4 mg reduces progression from pre-diabetes to T2D by roughly 60–73% over 3 years. If you have A1C 5.8–6.4% at baseline and would likely progress to T2D in the next 5 years without treatment, the expected-value savings from avoided diagnosis are substantial.
Cardiovascular event reduction. SELECT (semaglutide 2.4 mg in patients with established CVD and BMI ≥ 27, N=17,604, 39.8 months median follow-up): 20% relative reduction in the composite endpoint of CV death, non-fatal MI, and non-fatal stroke. A prevented MI is approximately $50,000–$100,000 in acute-care costs plus long-term cardiology follow-up; a prevented stroke often $100,000+ in acute + rehab. For a 60-year-old with prior MI, the expected-value savings from a 20% MACE reduction are in the thousands per year.
Sleep apnea resolution. SURMOUNT-OSA (tirzepatide in adults with moderate-to-severe OSA and obesity): apnea-hypopnea index (AHI) fell 25–30 events/hour at 52 weeks on tirzepatide vs. 5–6 on placebo. A substantial minority of patients resolved from moderate-severe to mild OSA, eliminating the need for CPAP ($800–$1,200/year in supplies, studies, and follow-up visits).
The STEP, SURMOUNT, and SELECT numbers you should anchor on
Four pivotal trials anchor the downstream-savings case:
- STEP 1 (Wilding et al., NEJM 2021): semaglutide 2.4 mg produced 14.9% TBWL at 68 weeks vs 2.4% on placebo. 86% of patients achieved ≥5% TBWL, 50% ≥15%. Every 5% of TBWL roughly corresponds to 5–10 mmHg systolic BP reduction, 5–15 mg/dL LDL reduction, 20–40% reduction in liver fat on MRI-PDFF, and AHI reduction of 5–15 events/hour in obese OSA patients.
- SURMOUNT-1 (Jastreboff et al., NEJM 2022): tirzepatide 15 mg produced 22.5% TBWL at 72 weeks. Triglycerides dropped 25–30%, systolic BP ~8 mmHg, A1C 0.5 pp in normoglycemic patients.
- SELECT (Lincoff et al., NEJM 2023): 20% MACE reduction in non-diabetic CVD+overweight/obese adults on semaglutide 2.4 mg. Number needed to treat ~67 over 3.3 years to prevent one MACE event.
- STEP 2 / SURPASS (T2D cohorts): A1C reductions of 1.5–2.5 percentage points; UKPDS long-term data maps every 1 pp A1C reduction to ~14% fewer MIs and ~37% fewer microvascular complications over decades.
The health-savings math rests on these endpoints translating to real-world avoided care. At the population level they largely do; at the individual level your mileage depends on your baseline risk.
Medications you may taper or discontinue
- Antihypertensives: weight loss reliably lowers BP 5–10 mmHg systolic per 10 kg lost. Many patients can reduce or discontinue one BP medication. Annual savings: $300–$1,200 depending on agent and coverage.
- Statins: LDL reduction on GLP-1 is modest (SELECT: ~5 mg/dL reduction on semaglutide); most patients stay on statins. Some with mild baseline hyperlipidemia can reduce dose.
- Insulin / sulfonylureas: T2D patients adding GLP-1 often reduce insulin 20–30% and discontinue sulfonylureas. Insulin cost at retail can be $300+/month even with the Inflation Reduction Act $35 Medicare cap; commercial cash remains expensive.
- Osteoarthritis pain management: significant weight loss reduces knee OA symptoms markedly. Some patients reduce NSAID reliance or postpone joint replacement.
- GERD / PPI: weight loss often resolves reflux; dose reductions in PPI common.
The indirect savings few people count
Absenteeism and presenteeism cost roughly $1,500–$3,000/year per employee in obesity-related reduced productivity. Joint surgery deferral or avoidance (total knee replacement averages $25,000–$45,000 all-in). Fewer sick days. These do not appear on any pharmacy claim.
SELECT in plain English: the cardiovascular story
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) randomized 17,604 adults age ≥ 45 with established CVD and BMI ≥ 27 to semaglutide 2.4 mg or placebo weekly. Primary endpoint was a composite of CV death, non-fatal MI, or non-fatal stroke. Results, published NEJM 2023: 6.5% event rate on semaglutide vs 8.0% on placebo, HR 0.80, p < 0.001. The effect appeared to be only partly mediated by weight loss — suggesting direct cardiovascular mechanism (vascular inflammation, plaque stabilization, blood-pressure reduction, glycemic effects). The FDA added the cardiovascular risk reduction indication to Wegovy’s label in March 2024, which is the basis for expanded Medicare Part D coverage.
Where the math falls apart
Three honest caveats:
- Baseline risk must be real. If you do not have pre-diabetes, no T2D avoidance savings apply. If your BP is normal at baseline, no BP-med savings.
- Durability depends on staying on the drug. Most of the CV and metabolic benefits accrue while on therapy. STEP 4 (withdrawal) showed regain. If you stop, the offsetting savings partially reverse.
- ICER cost-effectiveness threshold: at list price, semaglutide 2.4 mg was estimated at ~$237,000 per QALY gained (ICER, 2022), above the $150,000 common threshold. Discounted self-pay (LillyDirect, NovoCare) or insured copays shift the ICER toward favorable.
FLOW, STEP-HFpEF, and the kidney/heart-failure extensions
Two newer trials extend the downstream-savings case beyond CV and T2D:
- FLOW (Perkovic et al., NEJM 2024): semaglutide 1 mg in T2D with CKD stage 2–4, N=3,533. 24% reduction in composite kidney failure / ≥50% eGFR loss / kidney or CV death. Dialysis initiation costs roughly $90,000–$110,000/year; a deferred dialysis start of 2–4 years is a major expected-value saving.
- STEP-HFpEF and STEP-HFpEF DM (Kosiborod et al., NEJM 2023 and 2024): semaglutide 2.4 mg in heart failure with preserved ejection fraction and obesity. Improved KCCQ-CSS score by ~7–9 points; reduced HF-hospitalization-or-urgent-visit rate. HFpEF hospitalizations cost $12,000–$18,000 per admission; a 25–30% reduction in events maps to several thousand dollars of avoided acute care per year in the HFpEF+obesity cohort.
If you have established CVD, CKD, or HFpEF, the “health savings” math becomes a meaningful driver of the treatment decision — often dominating the weight-loss calculus entirely.
Running the numbers for three scenarios
Pre-diabetic 45-year-old, BMI 34, no CVD. Avoids T2D progression: ~$12,000/yr expected value over 10 years. BP meds reduced: ~$600/yr. Productivity: $2,000/yr. 10-year total: ~$146,000. Drug cost at $6,000/yr × 10 years = $60,000. Net savings: ~$86,000.
60-year-old post-MI, BMI 30, no diabetes. SELECT-indicated. Avoided MACE expected value: ~$3,000–$5,000/yr. Other med reductions: ~$800/yr. 10-year total: ~$40,000. Drug at insured copay $50/mo = $6,000 over 10 years. Large positive.
35-year-old BMI 29, no comorbidity. Avoided risk future T2D: $2,000/yr expected. No current med reduction. 10-year avoided cost: ~$20,000. Drug at $6,000/yr × 10 = $60,000. Here the financial case rests almost entirely on quality-of-life and productivity, not avoided medical costs.
FAQ
How do I know if my pre-diabetes will actually progress without treatment?
Baseline A1C, fasting glucose, and family history are the main predictors. A1C ≥ 6.0% progresses at roughly 10%/year; 5.7–5.9% at 4–6%/year. Your PCP can run a risk calculator. The Diabetes Prevention Program data is the reference.
Can I negotiate a lower GLP-1 cost using these savings numbers?
If you have a self-insured employer plan, yes — HR benefits teams increasingly factor avoided-cost analyses into coverage decisions. Direct consumer negotiation with pharmacies rarely moves the needle.
Does the CV benefit require me to be on Wegovy specifically?
SELECT was semaglutide 2.4 mg. Ozempic (semaglutide up to 2 mg for T2D) has partial read-through but is not labeled for CV risk reduction in patients without diabetes. Tirzepatide has an ongoing CVOT (SURPASS-CVOT / SURMOUNT-MMO).
Are HSA dollars “worth more” because of these savings?
Every pre-tax dollar you spend on GLP-1 saves federal income tax + FICA — ~30% effective savings in most brackets. Combine that with avoided medical costs and the economics are meaningfully better than cash pay. See the HSA/FSA tool.
What is the “productivity” line item based on?
Obesity-related absenteeism and presenteeism estimates from the Milken Institute and Integrated Benefits Institute. For an office worker earning the US median ($60K), roughly 2–5% of wages are lost to obesity-related productivity effects, or $1,200–$3,000/year.